-
Something wrong with this record ?
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment
JR. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kaźmierczak, N. Lamanna, SM. O'Brien, CS. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, PS. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg,...
Language English Country England, Great Britain
Document type Journal Article
PubMed
39132937
DOI
10.2217/fon-2023-0849
Knihovny.cz E-resources
- MeSH
- Adenine * analogs & derivatives therapeutic use MeSH
- Drug Resistance, Neoplasm * MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell * drug therapy MeSH
- Protein Kinase Inhibitors * therapeutic use adverse effects MeSH
- Humans MeSH
- Piperidines * therapeutic use MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrazines therapeutic use MeSH
- Pyrazoles * therapeutic use MeSH
- Pyrimidines * therapeutic use MeSH
- Thiazoles therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BeiGene International GmbH Basel Switzerland
BeiGene USA San Mateo California USA
Blue Ridge Cancer Care Roanoke Virginia USA
Chao Family Comprehensive Cancer Center University of California Irvine California USA
Hematology and Oncology Masaryk University and University Hospital Brno Czech Republic
Herbert Irving Comprehensive Cancer Center Columbia University New York New York USA
Maria Skłodowska Curie National Research Institute of Oncology Krakow Poland
St James's University Hospital Leeds United Kingdom
Texas Oncology Tyler US Oncology Network Tyler Texas USA
The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China
The Alfred Hospital and Monash University Melbourne VIC Australia
The Department of Haematology Christchurch Hospital Christchurch New Zealand
The Department of Hematology and Transplantology Medical University of Gdańsk Gdańsk Poland
The Department of Medical Oncology Dana Farber Cancer Institute Boston Massachusetts USA
The Leukemia Department University of Texas M D Anderson Cancer Center Houston Texas USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24020008
- 003
- CZ-PrNML
- 005
- 20241024110930.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/fon-2023-0849 $2 doi
- 035 __
- $a (PubMed)39132937
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Brown, Jennifer R $u The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- 245 10
- $a Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment / $c JR. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kaźmierczak, N. Lamanna, SM. O'Brien, CS. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, PS. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, HA. Yimer, T. Salmi, MD. Wang, L. Fu, J. Li, K. Wu, A. Cohen, M. Shadman
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a piperidiny $x terapeutické užití $7 D010880
- 650 12
- $a adenin $x analogy a deriváty $x terapeutické užití $7 D000225
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $7 D015451
- 650 12
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 12
- $a pyrazoly $x terapeutické užití $7 D011720
- 650 12
- $a chemorezistence $7 D019008
- 650 12
- $a inhibitory proteinkinas $x terapeutické užití $x škodlivé účinky $7 D047428
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a pyraziny $x terapeutické užití $7 D011719
- 650 _2
- $a thiazoly $x terapeutické užití $7 D013844
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Eichhorst, Barbara $u The Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany
- 700 1_
- $a Hillmen, Peter $u St. James's University Hospital, Leeds, United Kingdom
- 700 1_
- $a Jurczak, Wojciech $u Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland
- 700 1_
- $a Kaźmierczak, Maciej $u The Department of Hematology & Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Lamanna, Nicole $u Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
- 700 1_
- $a O'Brien, Susan M $u Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
- 700 1_
- $a Tam, Constantine S $u The Alfred Hospital & Monash University, Melbourne, VIC, Australia
- 700 1_
- $a Qiu, Lugui $u The State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
- 700 1_
- $a Zhou, Keshu $u The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
- 700 1_
- $a Simkovic, Martin $u The Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic, & The First Faculty of Medicine, Charles University, Prague, & the Department of Internal Medicine, Prague, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Hematology & Oncology, Masaryk University & University Hospital, Brno, Czech Republic
- 700 1_
- $a Gillespie-Twardy, Amanda $u Blue Ridge Cancer Care, Roanoke, Virginia, USA
- 700 1_
- $a Ferrajoli, Alessandra $u The Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
- 700 1_
- $a Ganly, Peter S $u The Department of Haematology, Christchurch Hospital, Christchurch, New Zealand
- 700 1_
- $a Weinkove, Robert $u Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, & the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand
- 700 1_
- $a Grosicki, Sebastian $u The Department of Hematology & Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland
- 700 1_
- $a Mital, Andrzej $u The Department of Hematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland
- 700 1_
- $a Robak, Tadeusz $u The Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Osterborg, Anders $u The Department of Oncology-Pathology, Karolinska Institutet, Stockholm & the Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Yimer, Habte A $u Texas Oncology-Tyler, US Oncology Network, Tyler, Texas, USA
- 700 1_
- $a Salmi, Tommi $u BeiGene International GmbH, Basel, Switzerland
- 700 1_
- $a Wang, Megan-Der-Yu $u BeiGene USA, San Mateo, California, USA
- 700 1_
- $a Fu, Lina $u Formerly of BeiGene
- 700 1_
- $a Li, Jessica $u BeiGene (Beijing), Beijing, China
- 700 1_
- $a Wu, Kenneth $u BeiGene USA, San Mateo, California, USA
- 700 1_
- $a Cohen, Aileen $u BeiGene USA, San Mateo, California, USA
- 700 1_
- $a Shadman, Mazyar $u The Fred Hutchinson Cancer Center & the Department of Medicine, University of Washington, Seattle, USA
- 773 0_
- $w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 20, č. 12 (2024), s. 717-726
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39132937 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110924 $b ABA008
- 999 __
- $a ok $b bmc $g 2202317 $s 1231981
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 20 $c 12 $d 717-726 $e 20231213 $i 1744-8301 $m Future oncology (London, England) $n Future Oncol $x MED00008687
- LZP __
- $a Pubmed-20241015
